Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Sanofi looks outside healthcare for new CFO

Sanofi-Aventis has appointed Jrme Contamine as executive vice president and chief financial officer (CFO), effective March 16.

Bristol-Myers buys a-fib drug from Tokyo firms for $40M

Bristol-Myers Squibb has signed an agreement with Nissan Chemical Industries and Teijin Pharma Limited for the development and commercialization of a selective inhibitor for the maintenance of normal sinus rhythm in patients with atrial fibrillation, currently in phaseI development in Japan.

NEJM: New test could earlier identify heart disease that causes sudden death

Investigators at Beth Israel Deaconess Medical Center have demonstrated that a new immunohistochemical test is reliable in diagnosing arrhythmogenic right ventricular cardiomyopathy, according to a study in the March 12 issue of the New England Journal of Medicine.

Merck to pay $41B to merge with Schering-Plough

The boards of directors at Merck and Schering-Plough have unanimously approved a definitive agreement under which Merck and Schering-Plough will merge in a $41.1 billion stock and cash transaction.

Top eight diabetes drugs made $5B over the past year

In recent years the diabetes drug market and insulin market has shown remarkable growth, according to a report from Research & Markets, a Dublin, Ireland-based market research firm.

Sanofi claims victory in enoxaparin antitrust suit

A federal judge has dismissed Amphastar Pharmaceuticals' cross-claims that two subsidiaries of Sanofi-Aventis engaged in anti-competitive conduct and unfair competition by obtaining and enforcing invalid patents related to Aventis' anti-clotting drug Lovenox (enoxaparin).

FDA takes aim at Ranbaxy

The FDA has accused Ranbaxy of submitting falsified stability data in abbreviated new drug applications, which include information generated from the company's plant in Paonta Sahib, India. The agency said that new and pending applications referencing information from the facility will not be reviewed until the suspect data are validated.

Bristol Myers names Andreotti as new president

Bristol Myers Squibb has elected Lamberto Andreotti as president and a member of its board of directors, effective this week.

Displaying 2273 - 2280 of 2325

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup